LDX

Lumos Diagnostics Holdings

Health Care Equipment & Services

Lumos Diagnostics Holdings specializes in the development, manufacture, and distribution of point-of-care diagnostic tests and associated readers. The company is positioned as a leader in rapid diagnostics, offering unique solutions like FebriDx, which aids in differentiating bacterial from viral infections at the point of care.

Point-of-Care

Diagnostics

Healthcare

FebriDx

Shorted

short percentage0.00%

reported shorts10K

shares on issue792.446M

About

website

lumosdiagnostics.com

industry

Health Care Equipment & Services

address

Leydin Freyer, Level 4, 96-100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205

Connect

Key Metrics

market cap

$202.07M

eps$-0.01

More Health Care Equipment & Services Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

Point-of-Care

Diagnostics

Healthcare

FebriDx

Innovation

Company Overview

AI-generated company summary

Company History

Lumos Diagnostics was founded to address the need for rapid and accurate diagnostic solutions in healthcare. Over the years, the company has evolved by expanding its product offerings and securing key partnerships to enhance its market reach. A significant milestone was the development and commercialization of FebriDx, a test that has gained traction in various healthcare settings.

Competitive Advantages

Lumos Diagnostics offers a unique value proposition with its rapid diagnostic tests that provide quick and accurate results at the point of care. The company's FebriDx test is a competitive advantage, as it helps differentiate between bacterial and viral infections, reducing unnecessary antibiotic use. Additionally, Lumos has strong partnerships and a robust pipeline of innovative diagnostic solutions.

Risk Factors

•Regulatory challenges in obtaining approvals for new tests
•Competition from established diagnostic companies
•Dependence on successful commercialization of new products

Recent Developments

Last 6 months

In the past six months, Lumos Diagnostics has partnered with BARDA to support the FebriDx CLIA Waiver Study, aiming to expand the test's accessibility and market presence.

Key People

Leadership team at Lumos Diagnostics Holdings

Doug Ward

Chief Executive Officer

Doug Ward serves as the Chief Executive Officer and Managing Director, bringing extensive experience in leading healthcare companies.

Barrie Lambert

Chief Financial Officer

Barrie Lambert has over 20 years of international experience in high-growth companies within the medical sector, serving as the Chief Financial Officer.